Longer Lives Leave More Years With Illness as Cardiometabolic Disease Rises
Global lifespan gains outpace gains in healthy years. A review highlights cardiometabolic disease as a modifiable driver of this widening gap.
Summary
People are living longer worldwide, but gains in healthy years are not keeping pace. This narrative review examines global and regional trends in lifespan, healthy lifespan, and heart and metabolic diseases. Between 1990 and 2019, global life expectancy increased by 8.1 years, while healthy life expectancy increased by 6.6 years. Cardiovascular disease alone accounted for 19.2 million deaths in 2023. Even where cardiovascular death rates have fallen after accounting for age, population growth, aging, and rising metabolic risks have increased the overall burden. Poorer countries face infectious diseases alongside growing cardiometabolic illness; wealthier countries face more illness despite slowing lifespan gains. The practical message is to prioritize cardiovascular and metabolic prevention, not just longer survival. This summary uses only the abstract, which does not establish which interventions best close the gap.
Detailed Summary
Living longer does not necessarily mean spending those extra years in good health. A growing gap between lifespan and healthy lifespan means more time living with illness or disability. This review examines how heart and metabolic diseases contribute to that gap, making prevention relevant not just to avoiding early death but also to preserving independence and function in later life.
The authors conducted a narrative review of global and regional patterns in life expectancy and healthy life expectancy. They describe differences across economic development levels, regions, and demographic groups. The abstract covers historical changes extending from 1950 through 2023 and emphasizes cardiovascular disease, metabolic risks, population aging, and the uneven conditions that shape opportunities for prevention and access to primary care.
From 1950 to 2023, life expectancy increased by 25 years for women and 24 years for men. Between 1990 and 2019, overall life expectancy rose 8.1 years, while healthy life expectancy rose only 6.6 years. Cardiovascular disease accounted for 19.2 million deaths in 2023 and 437 million years of healthy life lost through disability or premature death, the review reports.
These trends coexist with falling cardiovascular death rates after accounting for age in many settings. Population growth, aging, and increasing metabolic risks can still raise total disease burden. For clinicians and readers, the implication is to prioritize prevention and management of cardiovascular and metabolic risks throughout adulthood, rather than treating longer survival alone as proof of better health during aging.
Regional patterns differ: poorer countries face infectious diseases alongside rising cardiometabolic illness, while wealthier countries face expanding illness despite slowing lifespan gains. This summary relies on the abstract only. The review does not test an intervention, and its abstract provides no systematic search methods or evidence grading. Its broad trends cannot establish causes or predict any individual patient's future health.
Key Findings
- Global life expectancy rose 8.1 years from 1990–2019, versus 6.6 years for healthy life expectancy, widening the gap by 1.5 years.
- Cardiovascular disease accounted for 19.2 million deaths and 437 million disability-adjusted life years worldwide in 2023.
- Declining cardiovascular death rates after age adjustment can coexist with rising total disease burden as populations grow and age.
- Prioritize cardiovascular and metabolic risk prevention; longer survival alone does not demonstrate better health or preserved function.
- Prevention strategies need regional tailoring because infectious disease burdens, metabolic risks, and primary care capacity differ.
Methodology
This narrative review examines global and regional life expectancy and healthy life expectancy trends, emphasizing cardiometabolic disease and demographic differences. The abstract reports historical population estimates but does not describe search methods, study selection criteria, or formal evidence grading.
Study Limitations
This summary is based on the abstract only; the full text was not available for assessment. As a narrative review without systematic methods described in the abstract, its completeness and risk of selection bias cannot be evaluated. Population-level trends cannot establish causation or quantify individual benefits from prevention.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: